Artax Biopharma presented preclinical data on Nck modulators for atopic dermatitis at the 2025 American Academy of Dermatology Annual Meeting. The data demonstrate the potential of Nck modulation to treat autoimmune skin diseases by regulating T cell activation. Specifically, the research highlighted the reduction of inflammation markers in animal models and the controlled release of cytokines from human immune cells.
This research is a critical step towards developing a new class of treatments for atopic dermatitis and other autoimmune diseases. Current therapies often rely on broad immunosuppression, which can leave patients vulnerable to infections. Nck modulation offers a more targeted approach by selectively impacting the faulty T cell activation responsible for these conditions. This precision could lead to improved efficacy and a better safety profile for patients, potentially transforming how these diseases are managed.
Key findings include a dose-dependent decrease in cytokine production from patient-derived cells exposed to dust mites, a common atopic dermatitis trigger. Furthermore, the oral Nck modulator AX-194 significantly reduced skin inflammation in an animal model. These results build on previous positive Phase 2a data for psoriasis, another autoimmune skin disease, further validating the potential of Nck modulation across a range of these conditions.
These promising preclinical results pave the way for further investigation of Nck modulators in other autoimmune diseases. Artax Biopharma is planning additional studies to explore the potential of this novel mechanism to correct erroneous T cell activation in dermal autoimmune disorders, ultimately aiming to develop much-needed, more targeted therapies. This innovative approach could shift the treatment paradigm for patients suffering from these debilitating conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
